Veru Inc. (VERU)

2.12
NASDAQ : Health Technology
Prev Close 2.11
Day Low/High 2.10 / 2.15
52 Wk Low/High 1.18 / 2.49
Avg Volume 130.90K
Exchange NASDAQ
Shares Outstanding 65.04M
Market Cap 137.23M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Veru To Ring NASDAQ Closing Bell On September 4th To Kick Off National Prostate Cancer Awareness Month

Veru To Ring NASDAQ Closing Bell On September 4th To Kick Off National Prostate Cancer Awareness Month

MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc.

Veru Reports Higher Net Revenues And Gross Profit For Its Fiscal 2019 Third Quarter

Veru Reports Higher Net Revenues And Gross Profit For Its Fiscal 2019 Third Quarter

Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist 3 Month Depot Formulation for Androgen Deprivation Had Successful PreNDA meeting with FDA for TADFIN...

Veru To Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call On August 8th

Veru To Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call On August 8th

MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Veru Inc.

Veru Announces Dismissal Of Lawsuit; Prevails On All Counts In Motion For Summary Judgment

Veru Announces Dismissal Of Lawsuit; Prevails On All Counts In Motion For Summary Judgment

MIAMI, July 18, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced the dismissal of litigation...

FDA Grants Fee Waiver For Tamsulosin DRS New Drug Application

FDA Grants Fee Waiver For Tamsulosin DRS New Drug Application

-- Provides $2.4 Million for Drug Product Development --

Veru Completes $10 Million Synthetic Royalty Financing On FC2 Business

Veru Completes $10 Million Synthetic Royalty Financing On FC2 Business

Immediate Non-Dilutive Financing to Further Drug Development

Veru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results

Veru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results

Veru Remains on Schedule to File 505(b)(2) Tamsulosin DRS New Drug Application in First Half Calendar 2018

TheStreet Quant Rating: D (Sell)